Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Dale A. Sander is CFO and Chief Corp. Deve. Off. at Humacyte. OQRO lists 3 transactions filed with the SEC under this name, the latest on May 20, 2026, each linked to the official Form 4.
CFO and Chief Corp. Deve. Off.
Disclosures on record
3
Companies involved
1
1 buy, median +44.2 pts vs S&P 500, beat it 1 of 1 time.
Average +44.2 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Apr 14, 2025 to Apr 14, 2025, measured from the first close after the filing. Past results, not a forecast.
1 purchase disclosed; 100% of the 1 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
HumacyteHUMA
3 disclosures · Apr 2025 – May 2026 · 1 sold · 1 bought
May 18, 2026Sold~$41Kdisclosed May 20
DetailsOfficial recordNov 16, 2025311Kdisclosed Nov 17
DetailsOfficial recordEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Apr 10, 2025Bought~$31Kdisclosed Apr 14
DetailsOfficial recordAs of the latest filing on , Dale A. Sander reported holding 307,813 shares of Humacyte (HUMA), worth about $172K at the last close of $1 (Nov 13, 2026): 267,213 held directly and 40,600 through a spouse. In the last 12 months, Dale A. Sander sold $41K in 1 sale.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Humacyte HUMA | 307,813 | 267K direct · 41K spouse | $1 | $172K | May 18, 2026 |
Is this Dale A. Sander’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Dale A. Sander bought shares on the open market in 2022 and 2025. Sales in 2 of the 5 years since 2022.
Dale A. Sander reported 3 open-market purchases and 2 sales since 2022; purchases in 2 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $41K1×1 trade |
| 2025 | $31K1×1 trade | — |
| 2024 | — | $263K1×1 trade |
| 2022 | $61K2×2 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated May 18, 2026, Dale A. Sander reported holding 307,813 shares of Humacyte (HUMA), of which 40,600 are held indirectly. At the last close of $1 on Nov 13, 2026, that is about $172K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Dale A. Sander reported 1 open-market sale worth $41K, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Dale A. Sander bought shares on the open market in 2022 and 2025. Sales in 2 of the 5 years since 2022.
In SEC filings since 2022: the latest open-market purchase is from 2025; the latest open-market sale is from 2026.
Humacyte (HUMA), from 2022 to 2026: 3 purchases and 2 sales.
Dale A. Sander reported 3 open-market purchases and 2 sales here, 2022 to 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.